2020-10-29 16:00Financial Performance - Operating revenue for the reporting period was ¥883,279,435.85, a decrease of 12.56% compared to the same period last year[8]. - Net profit attributable to shareholders of the listed company was ¥127,537,897.12, representing a slight increase of 2.13% year-on-year[8]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥101,542,973.46, down 35.02% compared to the same period last year[8]. - Basic earnings per share for the reporting period were ¥0.0915, a decrease of 8.59% year-on-year[8]. - The weighted average return on net assets was 1.26%, down 0.60% compared to the previous year[8]. - Total operating revenue for Q3 2020 was CNY 883,279,435.85, a decrease of 12.6% compared to CNY 1,010,151,349.28 in the same period last year[76]. - The company's operating profit for the current period is approximately 154.75 million, compared to 150.02 million in the previous period, reflecting an increase of about 4.5%[82]. - The net profit attributable to the parent company's owners is approximately 127.54 million, up from 124.88 million, indicating a growth of about 2.6%[82]. - The total comprehensive income attributable to the parent company's owners is approximately -30.33 million, compared to 201.14 million in the previous period, showing a significant decline[85]. - The company's revenue for the current period is approximately 277.98 million, down from 441.41 million, representing a decrease of about 37%[85]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥18,512,739,521.17, an increase of 21.46% compared to the end of the previous year[8]. - The company's cash and cash equivalents increased by 129.16% to CNY 2,928,107,184.47 compared to CNY 1,277,767,013.51 at the end of the previous year, attributed to increased fundraising from its Hong Kong listing[23]. - Trading financial assets rose by 444.28% to CNY 613,097,117.68, due to increased investments in short-term financial products using idle funds[23]. - The company's inventory increased by 40.85% to CNY 3,344,386,695.08, reflecting a rise in production in line with sales growth trends[23]. - The company reported a total current assets of approximately CNY 8.85 billion as of September 30, 2020, compared to CNY 5.99 billion at the end of the previous month, reflecting a significant increase of 47.8%[60]. - Total liabilities decreased to approximately CNY 7.14 billion from CNY 7.77 billion, showing a reduction of 8.2%[66]. - The company's total equity increased to approximately CNY 11.37 billion from CNY 7.47 billion, marking a growth of 52.5%[69]. - The total liabilities were reported at 6,663,698,557.45 CNY, with current liabilities at 4,996,561,137.55 CNY[126]. - The total current liabilities were CNY 2,718,804,350.38, with a slight increase of CNY 4,402,850.03[135]. Cash Flow - The net cash flow from operating activities was ¥115,697,104.31, a significant increase of 260.03% compared to the previous year[8]. - Net cash flow from investing activities was -¥1,537,910,388.39, a decrease of 781.84% year-on-year due to increased cash payments for financial products[28]. - Net cash flow from financing activities was ¥2,511,085,525.36, a significant increase of 5678.76% year-on-year due to cash raised from stock issuance in Hong Kong[28]. - The net increase in cash and cash equivalents was ¥834,678,951.15, reflecting a 330.18% increase year-on-year[28]. - Cash inflow from operating activities totaled approximately ¥3.8 billion, up from ¥3.64 billion year-over-year[109]. - The net cash flow from operating activities was a loss of approximately ¥129.85 million, an improvement from a loss of ¥151.46 million in the previous period[109]. - The net cash flow from financing activities was approximately ¥2.51 billion, a significant improvement from a net outflow of ¥45.01 million in the previous period[112]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,786[12]. - The largest shareholder, Shenzhen Le Ren Technology, held 32.31% of the shares, amounting to 474,029,899 shares[12]. - The company has not made any share repurchases during the reporting period[38]. Research and Development - R&D expenses decreased by 38.24% to CNY 69,407,687.52, primarily due to the exclusion of a subsidiary from consolidation since Q2 2019[25]. - Research and development expenses decreased to CNY 34,495,520.35 from CNY 54,048,691.20, a reduction of 36.2%[79]. - The company continues to focus on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[120]. Regulatory and Market Developments - The company received FDA approval for its subsidiary to register as a supplier of enoxaparin sodium in the U.S. market[31]. - All five specifications of enoxaparin sodium injection passed the consistency evaluation for generic drugs in China[31]. - The company has successfully registered its wholly-owned subsidiary as a supplier of enoxaparin sodium preparations in the US market[38]. - The company has committed to not engaging in any competitive business during the reporting period[40].